Market Indices
Sector Heatmap
CGEM — Cullinan Therapeutics, Inc. Common Stock
NasdaqCullinan Therapeutics, Inc. Common Stock
- O
- 14.76
- H
- 15.56
- L
- 14.59
- V
- 1.15M
CGEM — Latest News & Headlines
20 StoriesCullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History Yahoo! Finance Canada
$CGEM stock is down 20% today. Here's what we see in our data. - Quiver Quantitative
$CGEM stock is down 20% today. Here's what we see in our data. Quiver Quantitative
CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger - Stocktwits
CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger Stocktwits
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 7.1% - Here's What Happened - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 7.1% - Here's What Happened MarketBeat
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - Yahoo Finance UK
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history Yahoo Finance UK
Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases - Seeking Alpha
Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases Seeking Alpha
Cullinan Therapeutics, Inc. - Common Stock (CGEM) Stock Price, News, Quote & History - FinancialContent
Cullinan Therapeutics, Inc. - Common Stock (CGEM) Stock Price, News, Quote & History FinancialContent
Biotech Stocks Widely Dive. Here Are The Hardest Hit. - Investor's Business Daily
Biotech Stocks Widely Dive. Here Are The Hardest Hit. Investor's Business Daily
Pipeline Data Could Shape The Case For Cullinan Therapeutics Stock - Simply Wall Street
Pipeline Data Could Shape The Case For Cullinan Therapeutics Stock Simply Wall Street
Discipline and Rules-Based Execution in CGEM Response - news.stocktradersdaily.com
Discipline and Rules-Based Execution in CGEM Response news.stocktradersdaily.com
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Has Consensus Price Target of $33.71 According to Analysts - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Has Consensus Price Target of $33.71 According to Analysts MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Stock Rating Reaffirmed as "Buy" by BTIG Research - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Stock Rating Reaffirmed as "Buy" by BTIG Research MarketBeat
Cullinan Therapeutics (CGEM) Could Be 50% Below Fair Value On Phase 3 Zipalertinib Data - Yahoo Finance
Cullinan Therapeutics (CGEM) Could Be 50% Below Fair Value On Phase 3 Zipalertinib Data Yahoo Finance
Cullinan Therapeutics Initiates FDA NDA Submission for Zipalertinib Combo in First-Line EGFR Exon 20 Insertion NSCLC Following Phase 3 REZILIENT3 Results - Quiver Quantitative
Cullinan Therapeutics Initiates FDA NDA Submission for Zipalertinib Combo in First-Line EGFR Exon 20 Insertion NSCLC Following Phase 3 REZILIENT3 Results Quiver Quantitative
Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026 - Yahoo Finance
Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026 Yahoo Finance
510,325 Shares in Cullinan Therapeutics, Inc. $CGEM Purchased by Bank of America Corp DE - MarketBeat
510,325 Shares in Cullinan Therapeutics, Inc. $CGEM Purchased by Bank of America Corp DE MarketBeat
Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs - Yahoo Finance
Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs Yahoo Finance
Cullinan Therapeutics (NASDAQ:CGEM) Earns Buy Rating from HC Wainwright - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Earns Buy Rating from HC Wainwright MarketBeat
Cullinan Therapeutics (CGEM) Is Down 18.2% After Strong Zipalertinib Phase 3 Lung Cancer Data Release – Has The Bull Case Changed? - Yahoo Finance
Cullinan Therapeutics (CGEM) Is Down 18.2% After Strong Zipalertinib Phase 3 Lung Cancer Data Release – Has The Bull Case Changed? Yahoo Finance
Cullinan Therapeutics (CGEM) Could Be 35% Undervalued As Phase 3 Lung Cancer Data Lands - Simply Wall Street
Cullinan Therapeutics (CGEM) Could Be 35% Undervalued As Phase 3 Lung Cancer Data Lands Simply Wall Street